Navigation Links
Doctor-aided suicide: No slippery slope
Date:9/26/2007

oming incompetent or are perceived to be suffering intolerably.

Battins team analyzed data on assisted suicide and voluntary active euthanasia in the Netherlands during 1985-2005 data taken from four government studies and several smaller ones. They analyzed Oregon Department of Human Services annual reports for 1998-2006, and surveys of physicians and hospice professionals.

Those Who Ask to Die are Not the Underprivileged

The findings fell into three categories, based on the strength of the data. The researchers found:

  • Direct evidence that elderly people, women and uninsured people do not die in disproportionate numbers where physician-assisted death is legal, but AIDS patients do. (The insurance data is from Oregon only; everyone is insured in the Netherlands.)

  • Evidence that is partly direct and partly inferred showing that physician-assisted death does not kill disproportionate numbers of people who are poor, uneducated, racial and ethnic minorities, minors, or people with chronic physical or mental disabilities or chronic but not terminal illnesses.

  • Evidence that is based on inference or that is partly contested showing that people with psychiatric illness including depression and Alzheimers disease are not likely to die in lopsided numbers.

Those who received physician-assisted dying appeared to enjoy comparative social, economic, educational, professional and other privileges, the researchers write.

The researchers noted that in both Oregon and the Netherlands, people who received a doctors help in dying averaged 70 years old, and 80 percent were cancer patients.

As for AIDS, during nine years of the Oregon Death with Dignity Act, only six patients with the disease died with physician assistance 2 percent of all deaths under the law. Yet, the researchers write, persons with AIDS were 30 times more likely to use assis
'/>"/>

Contact: Lee Siegel
leesiegel@ucomm.utah.edu
801-581-8993
University of Utah
Source:Eurekalert

Page: 1 2 3 4

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...5 /PRNewswire-FirstCall/ -- Lung cancer patients,w...s may fare better as a,result, according to data f...linical trial. Data from the trial, which involved... injection), will be presented at the 44th Annual,...gy (ASCO) in Chicago,Ill., May 30 -- June 3, 2008...
(Date:5/15/2008)...h the goal of tailoring cancer treatment for each ...edical Center today presented a study suggesting a...assess treatment efficacy for patients with metast...and sometimes months to determine if a particular ...at long to observe any significant radiographic ch...
(Date:5/15/2008)...coxib, the anti-inflammatory medication also known... and reduces a specific proliferation measurement ...a study from The University of Texas M. D. Anderso...nificance of COX-2 inhibition toward preventing lu...ing the disease. , The study is the first large ...
(Date:5/15/2008)... 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharm...GTEC) ("Genesis" or,the "Company"), a U.S. pharmac...he People,s Republic of China, today announced its... 2008, the Company,s third quarter of its,fiscal y...r the quarter,with the U.S. Securities Exchange Co...
Breaking Medicine News(10 mins):Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12
...ew treatment has been discovered for pancreatic ca...ck Medical Center, according to the Annals of Surg...were studied responded to the therapy which is rep...ntributes towards reducing the size of the tumors ...
...h increasing global fear regarding the spread of t...s reported that a 10-year-old Chinese girl is the ...he victim hails from the southern Guangxi region a...pneumonia since November 23. A test done to analy...
...mone replacement therapy could be the answer to pr... Prof Jay Kaplan, from Wake Forest University Bapt...e Pill and even HRT is generally frowned upon sinc... developing breast cancer, but this new research s...
... the first time in India fish sales is maximum. S..., white pomfret, sole, salmon, cod, red snapper// ... Indians and foreigners on a time. Delicious sea ...re unloaded in the van by 3’o clock in the afterno...
Other Medicine News:Health News:Bird Flu Infection Of Chinese Girl Prompts Fear Of Spread Across Asia 2Health News:Increased Fish market enables hike in fish pricing 2
(Date:5/15/2008).../- Medivation, Inc.,(Nasdaq...g Phase 1-2 clinical,trial of its novel androgen r...an oral presentation at the 44th American Society ...ago., Session title: New Targeted Strategies fo...time: Monday, June 2 at 11:30 a.m. Central Time A...
(Date:5/15/2008)...May 15 /- Cytopia Limited,(...s upcoming oral,presentation on CYT997 at the 2008...l Oncology (ASCO) will be accessible to the public...pm on Thursday 15 May (US EDT)., The oral present...ovel,cytotoxic and vascular disrupting agent, in p...
(Date:5/15/2008)... 15 /- Sanofi-aventis,(EURO...ings from the,landmark ATHENA study showed Multaq(...tment of patients with atrial fibrillation or atri...ospitalizations or death from any,cause by a stati...he study,primary endpoint. The ATHENA results will...
(Date:5/15/2008)...wire/ -- CenterWatch, a publishing and,information... clinical,trials, finds that investigative sites a... capture) systems. More than 75% of respondents to...ad been trained on three or more,EDC systems. In a...ss of,their EDC training had improved., State of ...
Breaking Medicine Technology:Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2A Phase II Randomized Double Blind Placebo Controlled Dose Escalating Study Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of 782 1A Phase II Randomized Double Blind Placebo Controlled Dose Escalating Study Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of 782 2Honor Society of Nursing Recognizes Researcher of HIV Risk Prevention for Poor and Underserved 779 1Honor Society of Nursing Recognizes Researcher of HIV Risk Prevention for Poor and Underserved 779 2Honor Society of Nursing Recognizes Researcher of HIV Risk Prevention for Poor and Underserved 779 3U S Food and Drug Administration Approves ABILIFY 28R 29 28aripiprazole 29 for Adolescent Patients With Schizophrenia 5712 1U S Food and Drug Administration Approves ABILIFY 28R 29 28aripiprazole 29 for Adolescent Patients With Schizophrenia 5712 2U S Food and Drug Administration Approves ABILIFY 28R 29 28aripiprazole 29 for Adolescent Patients With Schizophrenia 5712 3U S Food and Drug Administration Approves ABILIFY 28R 29 28aripiprazole 29 for Adolescent Patients With Schizophrenia 5712 4U S Food and Drug Administration Approves ABILIFY 28R 29 28aripiprazole 29 for Adolescent Patients With Schizophrenia 5712 5U S Food and Drug Administration Approves ABILIFY 28R 29 28aripiprazole 29 for Adolescent Patients With Schizophrenia 5712 6U S Food and Drug Administration Approves ABILIFY 28R 29 28aripiprazole 29 for Adolescent Patients With Schizophrenia 5712 7U S Food and Drug Administration Approves ABILIFY 28R 29 28aripiprazole 29 for Adolescent Patients With Schizophrenia 5712 8Synchrotron radiation illuminates how babies protective bubble bursts 1711 1Synchrotron radiation illuminates how babies protective bubble bursts 1711 2
...ration,Biopharmaceuticals today announced the pres...pment of new, proprietary forms of,recombinant Fac...ta,were highlighted in an oral presentation and a ...ational Society on Thrombosis and,Haemostasis (IST....D., Associate Professor, UNC School of,Medicine, ...
...B8F) announces today,that it has received very pos...e IIb/III clinical trial started in autumn 2006. B...e 5-aminolevulinic acid,(ALA) with the nanoemulsio...to placebo in the treatment of actinic keratosis. ...eliminates tumor tissue,through a combination of a...
Other Medicine Technology:Inspiration Biopharmaceuticals Presents Data From Hemophilia,Program at International Society On Thrombosis and Haemostasis,(ISTH) Annual Meeting 2Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis 2
Contour I pouches are light as a feather and feature our tapered SoftFlex skin barrier for comformability, flexbility and comfort. All Contour I pouches have ComfortWear panels that keep skin cool an
Inquire
Inquire
Superior Skin Care...Convex FlexWear skin barrier is secure and provides extended weartime. Security and confidence assured with internal non-reflux valves and a drain valve that allows regulation of
Medicine Products: